University of Toronto, SickKids develop chemically modified tRNA platform for cystic fibrosis nonsense mutations

A chemically modified, lipid nanoparticle-delivered suppressor transfer RNA platform has restored functional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cell lines, a mouse model, and patient-derived organoids, according to a study published August 27, 2026 in Science. The work, with leading contributors including Jingan Chen and Bowen Li, among others, at the University of Toronto and the Hospital for Sick Children (SickKids) in Toronto, addresses a subset of cystic fibrosis (CF) patients — those carrying nonsense mutations — for whom existing CFTR modulator drugs offer little benefit.

Roughly 10% of people with CF carry nonsense mutations that introduce a premature termination codon (PTC) into the CFTR messenger RNA, causing the ribosome to halt translation early and produce a truncated, nonfunctional protein. Small-molecule read-through agents such as ataluren (PTC124, PTC Therapeutics), which completed a failed Phase III confirmatory trial in CF (NCT01140451), and the aminoglycoside analogue ELX-02 (Eloxx Pharmaceuticals), which failed Phase II, have not demonstrated sufficient efficacy in this population. The new platform takes a mechanistically distinct approach: engineering tRNA molecules to decode PTCs as sense codons, inserting the correct amino acid and allowing the ribosome to produce full-length CFTR protein.

Chemical modification as the central innovation

The platform combines two components: suppressor tRNAs (sup-tRNAs) with anticodons redesigned to read through PTCs, and a purpose-built lipid nanoparticle (LNP) formulation designated TTP-3. The key chemical advance is site-specific incorporation of N1-methyladenosine (m¹A) at positions 57 or 58 of the tRNA. The paper reports that this single modification increased PTC readthrough by up to 10.6-fold for an arginine sup-tRNA compared with unmodified controls, while simultaneously enhancing aminoacylation efficiency, prolonging functional persistence in cells, and reducing innate immune activation — recapitulating the modification patterns of endogenous mature tRNAs that protect them from immune detection.

TTP-3 was identified from a screen of more than 1,000 ionizable lipids specifically optimized for structured tRNA cargo, which the authors report behaves differently from the linear mRNA for which existing LNP formulations were designed. Intratracheal administration in CFTR R553X knock-in mice confirmed pulmonary delivery to airway epithelial and progenitor cells, tracked using a Mango II RNA aptamer inserted into the sup-tRNA for in vivo biodistribution imaging.

Functional restoration across three model systems

In CFTR-mutant bronchial epithelial cells, treatment restored both CFTR protein expression and chloride channel activity. In R553X knock-in mice, sup-tRNA/TTP-3 treatment produced measurable CFTR-dependent intestinal organoid swelling — a functional readout of ion transport reflecting full-length protein production rather than mere expression. In patient-derived organoids carrying a complex CFTR genotype, co-treatment with the sup-tRNA platform and elexacaftor/tezacaftor/ivacaftor (Trikafta, Vertex Pharmaceuticals) produced enhanced CFTR functional restoration compared with either approach alone, consistent with additive or complementary activity between the two approaches.

Competitive context

The most direct clinical comparator is Cambridge, Massachusetts-based Alltrna (a Flagship Pioneering company), whose engineered sup-tRNA AP003 — targeting arginine-to-TGA PTCs in rare genetic liver diseases via a systemically administered, liver-directed LNP — became the first tRNA therapeutic to enter human trials when Australia's Therapeutic Goods Administration cleared a Phase I single ascending dose study in healthy volunteers in March 2026. AP003 uses a mechanistically similar approach but differs in indication, delivery route, and target tissue.

In the CF-specific inhaled LNP space, the most advanced program is ARCT-032 (Arcturus Therapeutics), an inhaled LNP-based therapy in an active Phase II trial (NCT06747858) that has released interim data reported as safe, well tolerated, and showing early signs of clinical activity in Class I CF patients carrying nonsense mutations — the same population the sup-tRNA platform targets. Vertex's inhaled mRNA candidate VX-522 (NCT05668741) was terminated in Q1 2026 due to persistent tolerability issues. Spirovant Sciences has dosed the first patient in its SAAVe Phase I/II trial of an aerosol-delivered AAV gene therapy for CF nonsense mutations. ReCode Therapeutics is running a Phase II trial of its inhaled CFTR mRNA/LNP candidate RCT2100 (NCT06237335), with a separate Phase IIa combination study reported as fully enrolled with results expected by end of 2026.

Translational stage and limitations

The TTP-3/sup-tRNA platform remains preclinical, and important safety and translational questions remain. An accompanying Science Perspective highlighted dose-dependent pulmonary inflammation observed in mice following LNP administration, underscoring the need to establish whether repeat inhaled dosing can achieve therapeutic exposure without unacceptable respiratory toxicity. The in vivo efficacy data also derive from a limited number of models, including a single CFTR nonsense-mutation mouse model. The authors describe the platform as potentially applicable to other genetic diseases sharing the same nonsense codon class, though no data in non-CFTR disease models are presented.

---

Spot something wrong? Report an issue with this article